Adoptive Transfer of T cell Receptor-engineered T cells to treat hepAtocellular Carcinoma recurrence after liver Transplantation: a preclinical feasibility study

Adoptive Transfer of T cell Receptor-engineered T cells to treat hepAtocellular Carcinoma recurrence after liver Transplantation: a preclinical feasibility study - ATTRACT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47991

Enrollment

Registered

2019-10-28

Start date

2019-12-01

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Patients diagnosed with autoimmune hepatitis - Age: 18 years or older - Written informed-consent

Exclusion criteria

Exclusion criteria: - Patients with current use of immune suppressive agents/medication, not other specified - Patients with an immunocompromised medical condition, not other specified - Patients who refuse to participate in the study (refusing blood donation) - Patients that for medical reasons are judged unfit to donate blood by the treating physicians

Design outcomes

Primary

Measure	Time frame
(a series of) TCR(s) that have a high affinity and show exclusive recognition of liver antigens when presented by HLA molecules of liver transplant recipients, and that can safely be used in a future clinical trial of adoptive T cell therapy for HCC recurrence after LTx.	—

Secondary

Measure	Time frame
N/A.	—

Countries

Netherlands

Outcome results